Forza Wealth Management LLC Sells 548 Shares of Bristol-Myers Squibb (NYSE:BMY)

Forza Wealth Management LLC trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,075 shares of the biopharmaceutical company’s stock after selling 548 shares during the quarter. Forza Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $1,135,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of BMY. Cooper Financial Group boosted its position in shares of Bristol-Myers Squibb by 2.0% in the 4th quarter. Cooper Financial Group now owns 14,152 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 279 shares in the last quarter. Wedmont Private Capital boosted its position in shares of Bristol-Myers Squibb by 29.5% in the 4th quarter. Wedmont Private Capital now owns 10,487 shares of the biopharmaceutical company’s stock worth $586,000 after purchasing an additional 2,392 shares in the last quarter. Talbot Financial LLC boosted its position in shares of Bristol-Myers Squibb by 6.2% in the 4th quarter. Talbot Financial LLC now owns 99,996 shares of the biopharmaceutical company’s stock worth $5,656,000 after purchasing an additional 5,813 shares in the last quarter. CHICAGO TRUST Co NA boosted its position in shares of Bristol-Myers Squibb by 17.3% in the 4th quarter. CHICAGO TRUST Co NA now owns 22,204 shares of the biopharmaceutical company’s stock worth $1,256,000 after purchasing an additional 3,270 shares in the last quarter. Finally, Brookstone Capital Management boosted its position in shares of Bristol-Myers Squibb by 11.0% in the 4th quarter. Brookstone Capital Management now owns 186,155 shares of the biopharmaceutical company’s stock worth $10,529,000 after purchasing an additional 18,516 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BMY. Bank of America reiterated a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $55.00 to $73.00 in a research note on Tuesday, November 12th. TD Cowen upped their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Finally, UBS Group upped their price objective on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 9th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $56.27.

Bristol-Myers Squibb Price Performance

Shares of BMY traded down $0.38 during midday trading on Monday, hitting $55.45. 4,028,417 shares of the company traded hands, compared to its average volume of 9,204,139. The firm has a 50 day moving average of $57.44 and a 200-day moving average of $51.56. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The stock has a market cap of $112.46 billion, a price-to-earnings ratio of -15.45, a PEG ratio of 15.20 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same period in the prior year, the company posted $2.00 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.47%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio is -69.08%.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.